IndraLab
Statements
sparser
"It has previously been demonstrated that the Hsp90 inhibitor, geldanamycin, inhibits hERG trafficking, presumably through an Hsp90-dependent mechanism. xref Given the intense pharmaceutical interest in the development of Hsp90 inhibitors as therapies for cancer and other diseases, the importance of identifying the isoform dependency of this client protein is clear, as pan -inhibition may result in undesired effects."